Promis Neurosciences Stock Performance
| PMN Stock | USD 0.50 0.03 6.38% |
ProMIS Neurosciences holds a performance score of 6 on a scale of zero to a hundred. The company holds a Beta of 1.32, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ProMIS Neurosciences will likely underperform. Use ProMIS Neurosciences value at risk and the relationship between the skewness and relative strength index , to analyze future returns on ProMIS Neurosciences.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ProMIS Neurosciences are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, ProMIS Neurosciences displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:60 | Last Split Date 2022-06-28 |
1 | ProMIS Neurosciences Secures Funding to Enhance Therapeutic Development | 07/22/2025 |
2 | Acquisition by Altstiel Larry Douglas of 175000 shares of ProMIS Neurosciences at 1.0 subject to Rule 16b-3 | 07/25/2025 |
3 | Insider Trading | 08/14/2025 |
4 | Promis Neurosciences chief scientific officer buys 14,595 in shares - MSN | 08/18/2025 |
5 | ProMIS Neurosciences Inc. Breaks Below Key Support Level - 2025 Technical Patterns Real-Time Volume Trigger Notifications - thegnnews.com | 08/22/2025 |
6 | Ranking ProMIS Neurosciences Inc. among high performing stocks via tools - Dividend Hike Weekly Consistent Profit Watchlists - Newser | 08/26/2025 |
7 | Why ProMIS Neurosciences Inc. is moving today - Portfolio Risk Summary Technical Entry and Exit Alerts - Newser | 08/29/2025 |
8 | Is ProMIS Neurosciences Inc. stock entering bullish territory - Trade Risk Assessment AI Based Trade Execution Alerts - Newser | 09/02/2025 |
9 | Is ProMIS Neurosciences Inc. stock entering bullish territory - Share Buyback Weekly Watchlist for Consistent Profits - Newser | 09/05/2025 |
10 | Acquisition by Altstiel Larry Douglas of 165000 shares of ProMIS Neurosciences at 0.45 subject to Rule 16b-3 | 09/22/2025 |
11 | ProMIS Neurosciences Amends Employment Agreement with CSO - TipRanks | 09/30/2025 |
| Begin Period Cash Flow | 12.6 M | |
| Total Cashflows From Investing Activities | -693.00 |
ProMIS Neurosciences Relative Risk vs. Return Landscape
If you would invest 40.00 in ProMIS Neurosciences on July 8, 2025 and sell it today you would earn a total of 10.00 from holding ProMIS Neurosciences or generate 25.0% return on investment over 90 days. ProMIS Neurosciences is generating 1.623% of daily returns assuming volatility of 20.9974% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than ProMIS, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
ProMIS Neurosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProMIS Neurosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProMIS Neurosciences, and traders can use it to determine the average amount a ProMIS Neurosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0773
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | PMN | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 21.0 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.62 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average ProMIS Neurosciences is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProMIS Neurosciences by adding it to a well-diversified portfolio.
ProMIS Neurosciences Fundamentals Growth
ProMIS Stock prices reflect investors' perceptions of the future prospects and financial health of ProMIS Neurosciences, and ProMIS Neurosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProMIS Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -2.81 | ||||
| Current Valuation | 19.71 M | ||||
| Shares Outstanding | 51.81 M | ||||
| Price To Book | 2.42 X | ||||
| Price To Sales | 5,168 X | ||||
| Gross Profit | (21.1 M) | ||||
| EBITDA | (16.83 B) | ||||
| Net Income | 2.78 M | ||||
| Cash And Equivalents | 8.95 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 2.42 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 5.42 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (27.18 M) | ||||
| Earnings Per Share | (0.07) X | ||||
| Market Capitalization | 25.8 M | ||||
| Total Asset | 18.91 M | ||||
| Retained Earnings | (90.69 B) | ||||
| Working Capital | 16.69 M | ||||
About ProMIS Neurosciences Performance
By examining ProMIS Neurosciences' fundamental ratios, stakeholders can obtain critical insights into ProMIS Neurosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ProMIS Neurosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.08) | (1.13) | |
| Return On Tangible Assets | 146.94 | 154.29 | |
| Return On Capital Employed | -1 K | -958 | |
| Return On Assets | 146.94 | 154.29 | |
| Return On Equity | 168.54 | 176.96 |
Things to note about ProMIS Neurosciences performance evaluation
Checking the ongoing alerts about ProMIS Neurosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProMIS Neurosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProMIS Neurosciences is way too risky over 90 days horizon | |
| ProMIS Neurosciences has some characteristics of a very speculative penny stock | |
| ProMIS Neurosciences appears to be risky and price may revert if volatility continues | |
| ProMIS Neurosciences has high likelihood to experience some financial distress in the next 2 years | |
| ProMIS Neurosciences has about 8.95 M in cash with (27.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: ProMIS Neurosciences Amends Employment Agreement with CSO - TipRanks |
- Analyzing ProMIS Neurosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProMIS Neurosciences' stock is overvalued or undervalued compared to its peers.
- Examining ProMIS Neurosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProMIS Neurosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProMIS Neurosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProMIS Neurosciences' stock. These opinions can provide insight into ProMIS Neurosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.